In last trading session, Iterum Therapeutics Plc (NASDAQ:ITRM) saw 1.45 million shares changing hands with its beta currently measuring 2.85. Company’s recent per share price level of $1.39 trading at $0.28 or 25.23% at ring of the bell on the day assigns it a market valuation of $48.07M. That closing price of ITRM’s stock is at a discount of -117.27% from its 52-week high price of $3.02 and is indicating a premium of 41.73% from its 52-week low price of $0.81. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.34 million shares which gives us an average trading volume of 410.04K if we extend that period to 3-months.
For Iterum Therapeutics Plc (ITRM), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 1 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 1 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of 0 in the current quarter.
Iterum Therapeutics Plc (NASDAQ:ITRM) trade information
Upright in the green during last session for gaining 25.23%, in the last five days ITRM remained trading in the green while hitting it’s week-highest on Wednesday, 04/23/25 when the stock touched $1.39 price level, adding 2.11% to its value on the day. Iterum Therapeutics Plc’s shares saw a change of -21.47% in year-to-date performance and have moved 24.11% in past 5-day. Iterum Therapeutics Plc (NASDAQ:ITRM) showed a performance of -2.80% in past 30-days. Number of shares sold short was 1.5 million shares which calculate 5.57 days to cover the short interests.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 29.27% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 21.35% while estimates for its earnings growth in next 5 years are of 7.26%.
Iterum Therapeutics Plc (NASDAQ:ITRM)’s Major holders
Insiders are in possession of 1.19% of company’s total shares while institution are holding 8.53 percent of that, with stock having share float percentage of 8.63%. Investors also watch the number of corporate investors in a company very closely, which is 8.53% institutions for Iterum Therapeutics Plc that are currently holding shares of the company. BLUE BELL PRIVATE WEALTH MANAGEMENT, LLC is the top institutional holder at ITRM for having 66.0 shares of worth $76.0. And as of 2024-06-30, it was holding 0.0004 of the company’s outstanding shares.
